Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 9/20 | 0.33 |
| ▸ | IDH2 | P48735 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17818720 | 0.97 | EPHX2 (0.39) | EPHX2KDM1AIDH1IDH2 | |
| SCHEMBL23097042 | 0.89 | EPHX2 (0.35) | EPHX2KDM1A | |
| SCHEMBL29253020 | 0.84 | — | — | |
| SCHEMBL21144175 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL22691254 | 0.82 | IDH1 (0.33) | EPHX2KDM1AIDH1IDH2 | |
| Trifluoroacetic Acid SCHEMBL29221249 | 0.82 | EPHX2 (0.41) | EPHX2KDM1AIDH1IDH2 | |
| Hydrochloric Acid SCHEMBL31717594 | 0.80 | EPHX2 (0.36) | EPHX2IDH1 | |
| SCHEMBL25700279 | 0.79 | KDM1A (0.35) | KDM1A | |
| SCHEMBL23169960 | 0.77 | KDM1A (0.34) | KDM1A | |
| SCHEMBL25050066 | 0.74 | KDM1A (0.31) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025224168-A1 | ARYL SULFONE AND SULFANONE DERIVATIVES AS OREXIN RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-30 | — | — | WO | disclosed |
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | THE UAB RESEARCH FOUNDATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| CN-118103377-A | Compounds constituting C20 modified salinomycin derivatives, process for obtaining the compounds, compositions containing the compounds and uses of said compounds | 菲莱克洛有限责任公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11916195-B2 | Electrolyte solution, electrochemical device, lithium ion secondary battery, and module | DAIKIN INDUSTRIES, LTD. (JP) | 2024-02-27 | — | — | US | disclosed |
| US-11916195-B2 | Electrolyte solution, electrochemical device, lithium ion secondary battery, and module | DAIKIN INDUSTRIES, LTD. (JP) | 2024-02-27 | — | — | US | disclosed |
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | ALKAHEST, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230346764-A1 | Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-Inhibitors | ALKAHEST, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| CN-116234552-A | Dual modulators of mGluR5 and 5-HT2A receptors and uses thereof | (株)倍宝尊 | 2023-06-06 | — | — | CN | disclosed |
| US-7314936-B2 | Deazapurines and uses thereof | EISAI CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| EP-1455792-B1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | HOFFMANN LA ROCHE (CH) | 2007-04-18 | — | — | EP | disclosed |
| WO-2007036733-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007006926-A2 | NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-18 | — | — | WO | disclosed |
| US-7019001-B2 | Substituted benzothiazole amide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-20040229893-A1 | Substituted benzothiazole amide derivatives | FLOHR ALEXANDER (CH) | 2004-11-18 | — | — | US | disclosed |
| EP-1455792-A1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-15 | — | — | EP | disclosed |
| US-6727247-B2 | ADENOSINE RECEPTOR LIGANDS IN A METHOD OF TREATMENT, CONTROL, OR PREVENTION OF CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMAN-LA ROCHE INC. | 2004-04-27 | — | — | US | disclosed |
| US-20030149036-A1 | Substituted benzothiazole amide derivatives | HOFFMAN-LA ROCHE INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003049741-A1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | EPHX2 4064/4885KDM1A 1088/4885IDH1 3017/4885 |
| US-20030149036-A1 | Substituted benzothiazole amide derivatives | ADORA2A, ADORA1, ADORA2B | EPHX2 2603/4885KDM1A 3927/4885IDH1 2332/4885 |
| US-20040229893-A1 | Substituted benzothiazole amide derivatives | ADORA2A, ADORA1, ADORA2B | EPHX2 2603/4885KDM1A 3927/4885IDH1 2332/4885 |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | EPHX2 1834/4885KDM1A 1720/4885IDH1 805/4885 |
| US-20230346764-A1 | Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-Inhibitors | CCR3, CCR1, CCR4 | EPHX2 336/4885KDM1A 2811/4885IDH1 4867/4885 |
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | CCR3, CCR1, CCR4 | EPHX2 607/4885KDM1A 3592/4885IDH1 4705/4885 |
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | HNRNPR, HNRNPAB, RBM3 | EPHX2 4790/4885KDM1A 3191/4885IDH1 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.